Ert Pompe denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Pompe Disease ERT — and Why It Rarely Holds Up

Step therapy denials require a patient to try and fail one or more "preferred" alternatives before the requested therapy is approved. For Pompe disease enzyme replacement therapy, this denial type is particularly vulnerable to appeal. Pompe disease is a rare, progressive lysosomal storage disorder with a very limited treatment landscape. The FDA has approved only a small number of ERT products for this indication, and there is no established clinical practice of trialing one before another in the same way step therapy applies to, for example, competing statins or biologics in a crowded drug class.

Blue Cross Blue Shield's step-therapy requirement must be evaluated against the plan's own exception criteria, which under federal step-therapy protections (applicable in many states and under certain federal plan rules) must include an exception pathway when the alternative is contraindicated, clinically inappropriate, or the patient has already tried and failed it.

## Federal Appeal Rights

ACA Section 2719 guarantees internal and external review for adverse benefit determinations on non-grandfathered plans. ERISA Section 503 protects plan participants in employer-sponsored plans. You have approximately four months from the final internal denial to request external review. Expedited review is available when a treatment delay would seriously jeopardize health or functional capacity — a standard that Pompe disease's progressive nature can often satisfy.

## What to Gather

• Diagnosis confirmation — muscle biopsy results, genetic testing confirming the pathogenic variant, GAA enzyme-activity assay, or equivalent documentation establishing the Pompe diagnosis.
• Disease severity and progression documentation — pulmonary function trend, motor function assessments, and any documentation of ambulatory or respiratory decline from the clinical chart.
• Prior ERT history — if the patient was previously on a different approved ERT product and switched, document the clinical rationale (tolerability, efficacy, prescriber judgment) with dates and outcomes.
• Prescriber letter addressing step-therapy criteria — the physician should explicitly address each "required first step" named in the BCBS policy and explain why it is clinically inappropriate or already completed.
• BCBS policy printout — retrieve the current step-therapy and exception criteria from the BCBS medical-policy library.

## Criteria-Mapping Structure

Create a table: left column lists each step-therapy requirement from the BCBS policy; right column provides the chart fact or clinical rationale that satisfies it or qualifies the patient for an exception. Where the policy lists an exception for clinical inappropriateness of the required first step, populate that column with specific documented reasons from the prescriber and chart.

## Process and Timeline

1. File the internal appeal in writing, within the plan's stated deadline. 2. Simultaneously request the specific criteria and clinical-review rationale BCBS used — you are entitled to these under ERISA. 3. If the internal appeal is denied, file for independent external review within four months. 4. Given the progressive and potentially irreversible nature of Pompe disease, assess whether the expedited review pathway applies.